Clinician and patient experiences when providing and receiving information and support for managing chemotherapy-induced peripheral neuropathy: A qualitative multiple methods study

Eur J Cancer Care (Engl). 2022 Jan;31(1):e13517. doi: 10.1111/ecc.13517. Epub 2021 Oct 12.

Abstract

Objective: To improve patient experience of chemotherapy-induced peripheral neuropathy (CIPN), it is crucial to identify how patients develop their understanding and perception of CIPN. A wider understanding of the experiences of clinicians who provide CIPN information and support is also needed. This study explored clinician and patient experience of the provision of care, information and support for CIPN.

Methods: Data were collected between July and November 2019 using multiple qualitative methods. Non-participant observations were undertaken in colorectal and breast cancer clinics and at clinician stations, including the observation of chemotherapy consultations between patients and clinicians. Semi-structured interviews with people with cancer and clinicians were also conducted. Data were analysed using inductive reflexive thematic analysis.

Results: Three major themes emerged: (1) CIPN is a hidden chemotherapy side effect, (2) assessment and management of CIPN is disconnected and (3) patients and clinicians expect openness in CIPN symptom reporting, information provision and management.

Conclusion: Findings show the need to address the lack of patients' overall familiarity with CIPN. Echoing earlier studies, our findings suggest that knowledge and understanding about CIPN among clinicians are limited or lacking. These insights from patient and clinicians' CIPN experiences can inform future interventions that may address the genuine needs of patients and enhance CIPN support.

Keywords: CIPN; cancer; chemotherapy; chemotherapy-induced peripheral neuropathy; qualitative.

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Patient Outcome Assessment
  • Peripheral Nervous System Diseases* / chemically induced

Substances

  • Antineoplastic Agents